cv301
Vaccineexperimental
Clinical trial activity
5 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02840994)
Timeline
Indications
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, active
CEACAM5 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cv301
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04491955 | Phase 2 | Sep 22, 2020 | National Cancer Institute (NCI) |
| NCT03628716 | Phase 2 | Aug 31, 2018 | Bavarian Nordic |
| NCT03376659 | Phase 1/Phase 2 (Phase 2) | Aug 8, 2018 | Bavarian Nordic, Emory University, George Mason University, Georgetown University, Indiana University, Johns Hopkins University, Mayo Clinic, MedImmune, National Cancer Institute (NCI), Thomas Jefferson University |
| NCT03315871 | Phase 2 | Mar 20, 2018 | National Cancer Institute (NCI) |
| NCT02840994 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2016 | Bavarian Nordic |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bavarian Nordic | For profit | 3 | 2 | 1 | 2016 |
| National Cancer Institute (NCI) | Government | 3 | 2 | 1 | 2018 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| George Mason University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2018 |
| MedImmune | For profit | 1 | 0 | 1 | 2018 |
| Thomas Jefferson University | Academic/Hospital | 1 | 0 | 1 | 2018 |
10 organizations
Page 1 / 1